NICE supports allowing technology assessment bodies to provide advice to drug industryBMJ 2014; 349 doi: https://doi.org/10.1136/bmj.g5035 (Published 13 August 2014) Cite this as: BMJ 2014;349:g5035
- Carole Longson, director, Centre for Health Technology Evaluation1,
- Nick Crabb, programme director, scientific affairs1,
- Leeza Osipenko, associate director, scientific advice1
- 1National Institute for Health and Care Excellence, Manchester M1 4BD, UK
We read, with much astonishment, the article by Wise claiming that “selling” scientific advice procedures enables institutional capture by drug companies.1 The National Institute for Health and Care Excellence (NICE) strongly supports the development of processes for the provision of parallel scientific advice between the European Medicines Agency and Health Technology Assessment (HTA) bodies to the developers of medicinal products.
The provision of scientific advice to …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial